Stock ALOPM ONCODESIGN PRECISION MEDICINE
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Oncodesign Precision Medicine

Equities

ALOPM

FR001400CM63

Market Closed - Euronext Paris
Other stock markets
 06:51:03 21/06/2024 pm IST 		5-day change 1st Jan Change
1.05 EUR 0.00% Intraday chart for Oncodesign Precision Medicine -4.55% -41.99%
15/05 Oncodesign Precision Medicine and Navigo Proteins GmbH Sign A Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents CI
25/01 Oncodesign Precision Medicine: fundraising on the horizon CF

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • For the past twelve months, EPS forecast has been revised upwards.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • One of the major weak points of the company is its financial situation.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
ONCODESIGN PRECISION MEDICINE Stock Oncodesign Precision Medicine
-41.99% 20.44M -
MODERNA, INC. Stock Moderna, Inc.
+34.61% 51.51B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-6.63% 39.03B
B
LONZA GROUP AG Stock Lonza Group AG
+34.92% 38.91B
A
CELLTRION, INC. Stock Celltrion, Inc.
-12.11% 26.68B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.00% 26.13B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-13.68% 19.91B
B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+43.25% 13.71B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.39% 12.38B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-4.50% 11.74B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ALOPM Stock
  4. Ratings Oncodesign Precision Medicine